For research use only. Not for therapeutic Use.
HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC50s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer[1][2].
HG-14-10-04 (example 10) has inhibitory activity against ALK kinase with an IC50 of 20 nM[1].
HG-14-10-04 (compound 17b) exhibits kinase inhibitory activity against EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS with IC50s of 15.6 nM, 22.6 nM and 124.5 nM, respectively[2].
| Catalog Number | I011923 |
| CAS Number | 1356962-34-9 |
| Synonyms | 5-chloro-4-(1H-indol-3-yl)-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidin-2-amine |
| Molecular Formula | C29H34ClN7O |
| Purity | ≥95% |
| InChI | InChI=1S/C29H34ClN7O/c1-35-13-15-37(16-14-35)20-9-11-36(12-10-20)21-7-8-26(27(17-21)38-2)33-29-32-19-24(30)28(34-29)23-18-31-25-6-4-3-5-22(23)25/h3-8,17-20,31H,9-16H2,1-2H3,(H,32,33,34) |
| InChIKey | HRYNCLKDKCPYBF-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)C5=CNC6=CC=CC=C65)Cl)OC |
| Reference | [1]. U.S. Pat. Appl. Publ. (2012), US 20120028924 A1 [2]. Chen H, et al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858. |
